ArticleAntibiotics (Basel, Switzerland)2019
Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections.
Article in Antibiotics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Small-colony variants of Staphylococcus aureus: hidden threat in chronic and recurrent infections.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Antimicrobial Functionalized Mesoporous Silica FDU-12 Loaded with Bacitracin.Molecules (Basel, Switzerland) · 2026Article
- Antibacterial Activity of a Novel Glycyrrhizic Acid-loaded Chitosan Composite NanogelCurrent drug delivery · 2026Article
- Progress in brucellosis immune regulation inflammatory mechanisms and diagnostic advances.European journal of medical research · 2025Review
- Nanoparticles in Antibacterial Therapy: A Systematic Review of Enhanced Efficacy against Intracellular Bacteria.ACS omega · 2025Review
- Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases.Journal of nanobiotechnology · 2024Review
- The Antimicrobial Potency of Mesoporous Silica Nanoparticles Loaded withPharmaceutics · 2024Article
- In Vitro Antimicrobial Studies of Mesoporous Silica Nanoparticles Comprising Anionic Ciprofloxacin Ionic Liquids and Organic Salts.Pharmaceutics · 2023Article
- Inulin-lipid hybrid (ILH) microparticles promote pH-triggered release of rifampicin within infected macrophages.Drug delivery and translational research · 2023Article
- Nanoparticles coated by chloramphenicol in hydrogels as a useful tool to increase the antibiotic release and antibacterial activity in dermal drug delivery.Pharmacological reports : PR · 2023Article
- Mesoporous Organosilica Nanoparticles to Fight Intracellular Staphylococcal Aureus Infections in Macrophages.Pharmaceutics · 2023Article
- State of the Art on Developments of (Bio)Sensors and Analytical Methods for Rifamycin Antibiotics Determination.Sensors (Basel, Switzerland) · 2023Review
- Combinatorial efficacy of Manuka honey and antibiotics in theFrontiers in cellular and infection microbiology · 2023Article
- Nano-Silica Carriers Coated by Chloramphenicol: Synthesis, Characterization, and Grinding Trial as a Way to Improve the Release Profile.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Mesoporous silica nanocarriers as drug delivery systems for anti-tubercular agents: a review.Royal Society open science · 2022Review
- Lipid-Polymer Hybrid Nanoparticles Enhance the Potency of Ampicillin againstACS infectious diseases · 2021Article
- Nanoparticle-Based Rifampicin Delivery System Development.Molecules (Basel, Switzerland) · 2021Article
- Nanomedicines for the Efficient Treatment of Intracellular Bacteria: The "ART" Principle.Frontiers in chemistry · 2021Review
- Recent Advances Toward the Use of Mesoporous Silica Nanoparticles for the Treatment of Bacterial Infections.International journal of nanomedicine · 2021Review
- Nanoparticles for treatment of bovineDrug delivery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases remain a major burden in today's world, causing high mortality rates and significant economic losses, with >9 million deaths per year predicted by 2030. Invasion of host cells by intracellular bacteria poses treatment challenges due to the poor permeation of antimicrobials into the infected cells. To overcome these limitations, mesoporous silica nanoparticles (MSNP) loaded with the antibiotic rifampicin were investigated as a nanocarrier system for the treatment of intracellular bacterial infection with specific interest in the influence of particle size on treatment efficiency. An intracellular infection model was established using small colony variants (SCV) of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.